VYNE VYNE Therapeutics Inc.

CIK 0001566044 50 ready 8-Ks latest August 13, 2026, 4:14 PM ET RSS · JSON

Activity: NORMAL 2 filings / 30d vs 1 baseline Risk accumulating: repeated leadership change (8)

Ready 8-Ks 50

Latest filing August 13, 2026, 4:14 PM ET

Top materiality 1.00

Event mix other_material ×23 · earnings ×15 · m_and_a ×5

Sentiment 7 pos · 10 neg · 33 neu

Latest earnings reported 2025-Q2

Executive change recent →

SHENANIGAN SCORE 2 / 7 see the board

Recent 8-K filings for VYNE

Highest-materiality recent filing

Yarrow Bioscience completes reverse merger with VYNE; Yarrow stockholders own 97% of combined company

July 28, 2026, 5:11 PM ET M&A materiality 1.00 neutral item 1.01 item 2.01 item 2.02 item 3.02 item 3.03 item 5.01 item 5.02 item 5.03 item 5.05 item 7.01 item 9.01 ◈ executive_change ×8

VYNE valued at $8.5M, Pre-Merger Yarrow at $272.9M; exchange ratio 0.7171 shares of new co per Yarrow share.
Pre-Merger Yarrow stockholders own ~97% of combined company; VYNE stockholders ~3%.

Read filing →

August 13, 2026, 4:14 PM ET M&A materiality 0.80 neutral item 2.02 item 9.01 item 7.01

Yarrow (fka VYNE) closes reverse merger with YB-101 developer; $100M cash, $71M net loss

Merger closed July 27, 2026: VYNE issued 2,130,731 shares at 0.7171 exchange ratio; 25.6M pre-funded warrants and 2.0M options converted.
July 30, 2026, 4:03 PM ET other material materiality 0.60 neutral item 8.01

Yarrow Bioscience exchanges shares for pre-funded warrants; warrant count dwarfs common shares

Exchanged 133,290 common shares for pre-funded warrants to purchase same number at $0.0001/share.
July 28, 2026, 5:11 PM ET M&A materiality 1.00 neutral item 1.01 item 2.01 item 2.02 item 3.02 item 3.03 item 5.01 item 5.02 item 5.03 item 5.05 item 7.01 item 9.01 ◈ executive_change ×8

Yarrow Bioscience completes reverse merger with VYNE; Yarrow stockholders own 97% of combined company

VYNE valued at $8.5M, Pre-Merger Yarrow at $272.9M; exchange ratio 0.7171 shares of new co per Yarrow share.
July 21, 2026, 8:14 AM ET other material materiality 0.65 neutral item 7.01 item 8.01 item 9.01

VYNE announces 1-for-50 reverse stock split and $17.3M special dividend for Yarrow merger

Reverse stock split at 1-for-50 reduces outstanding shares from ~33.4M to ~0.7M.
July 17, 2026, 8:41 PM ET other material materiality 0.60 neutral item 5.07

VYNE stockholders approve all proposals for merger with Yarrow Bioscience at special meeting

Proposal 1 (issuance of shares >20% and change of control) approved: 15,915,017 for, 137,159 against.
July 10, 2026, 8:06 AM ET dividend materiality 0.70 neutral item 7.01 item 8.01 item 9.01

VYNE declares special cash dividend of $0.38/share in connection with Yarrow merger

Estimated aggregate $16.5M special cash dividend ($0.38/share) declared; record date July 22, 2026.
March 11, 2026, 7:59 PM ET regulatory materiality 0.60 negative item 3.01 ◈ Listing & Compliance Notices

VYNE receives Nasdaq extension to Sept 7, 2026 to regain $1 bid price compliance

Company failed to regain minimum $1.00 bid price by original March 10, 2026 deadline.
December 17, 2025, 6:59 PM ET M&A materiality 0.95 negative item 1.01 item 3.02 item 5.01 item 5.02 item 7.01 item 9.01 ◈ Material Agreements

VYNE Therapeutics to merge with Yarrow Bioscience; Yarrow stockholders to own ~97% of combined company

Pro forma ownership: pre-Merger Yarrow stockholders ~97%, VYNE stockholders ~3%.
November 6, 2025, 6:59 PM ET earnings materiality 0.75 negative item 2.02 item 9.01

VYNE reports Q3 net loss $7.3M; cash $32.7M; strategic review ongoing

Net loss $7.3M ($0.17 per share) vs $12.2M ($0.29) in Q3 2024; revenue $0.2M from Finacea royalty.
September 12, 2025, 7:59 PM ET regulatory materiality 0.85 negative item 3.01 ◈ Listing & Compliance Notices

VYNE receives Nasdaq bid price deficiency notice; 180-day cure period to March 2026

Closing bid price of VYNE common stock below $1.00 for 30 consecutive business days.
August 14, 2025, 7:59 PM ET earnings materiality 0.75 negative item 2.02 item 5.02 item 9.01

VYNE Q2 net loss $5.8M; cash runway extended to H1 2027; two directors resign

Cash, equivalents and marketable securities $39.6M as of Jun 30, expected to fund ops into first half of 2027.
July 30, 2025, 7:59 PM ET other material materiality 0.90 negative item 2.02 item 8.01 item 9.01

VYNE Phase 2b Repibresib vitiligo trial misses F-VASI50, terminates extension, seeks partner

Primary endpoint F-VASI50 at Week 24 not met: 19.5% for 3% vs 23.4% vehicle (p=0.1245).
May 8, 2025, 7:59 PM ET earnings materiality 0.70 negative item 2.02 item 9.01

VYNE Q1 net loss $8.6M; VYN202 psoriasis trial on clinical hold; repibresib vitiligo data due mid-2025

Cash $50.3M; net loss $8.6M ($0.20/sh) vs $6.2M in Q1 2024.
March 6, 2025, 6:59 PM ET earnings materiality 0.60 neutral item 2.02 item 9.01

VYNE reports FY2024 net loss $39.8M; cash $61.5M; repibresib Phase 2b data due mid-2025

Cash & equivalents total $61.5M as of Dec 31, 2024; expected runway into 2H 2026.
December 23, 2024, 6:59 PM ET other material materiality 0.75 positive item 8.01 item 9.01

VYNE reports positive Phase 1a MAD data for VYN202; no AE, robust biomarker activity

VYN202 showed favorable safety with no drug-related AEs, including no thrombocytopenia or neutropenia.
November 7, 2024, 6:59 PM ET earnings materiality 0.70 neutral item 2.02 item 9.01

VYNE reports Q3 net loss $12.2M; VYN201 Phase 2b enrollment exceeds target, top-line mid-2025

Net loss of $12.2M ($0.29/sh) in Q3 2024 vs $6.6M ($2.01/sh) in Q3 2023, driven by higher R&D spend.
September 12, 2024, 7:59 PM ET other material materiality 0.65 positive item 8.01 item 9.01

VYNE Therapeutics reports positive Phase 1a SAD data for VYN202; no drug-related adverse events

VYN202 well tolerated across all dose groups; no serious or drug-related AEs, no clinically significant lab/ECG abnormalities.
August 14, 2024, 7:59 PM ET earnings materiality 0.65 neutral item 2.02 item 9.01

VYNE Therapeutics Q2 2024 net loss $9.4M; cash $78.1M funds milestones into 2025

Net loss of $9.4M ($0.22 EPS) vs $10.1M ($3.09 EPS) in Q2 2023.
May 9, 2024, 7:59 PM ET earnings materiality 0.60 neutral item 2.02 item 9.01 ◈ Earnings Releases

VYNE reports Q1 2024 net loss of $6.2M, cash $86M; vitiligo Phase 2b trial on track

Cash, equivalents, restricted cash and marketable securities of $86.0M as of March 31; runway through end of 2025.
February 29, 2024, 6:59 PM ET earnings materiality 0.70 neutral item 2.02 item 9.01 ◈ Earnings Releases

VYNE reports Q4/FY 2023 loss; cash $93.3M; VYN201 Phase 2b starts Q2 2024; VYN202 Phase 1a expected Q2 2024

Cash, cash equivalents, restricted cash and marketable securities $93.3M at Dec 31, 2023, providing runway through end of 2025.
November 13, 2023, 6:59 PM ET other material materiality 0.75 positive item 2.02 item 9.01 ◈ Earnings Releases

VYNE raises $88.2M, reports positive Phase 1b vitiligo data for VYN201

$88.2M private placement closed Nov 1; cash runway extended through end of 2025.
October 30, 2023, 7:59 PM ET other material materiality 0.80 positive item 1.01 item 1.02 item 2.02 item 3.02 item 5.08 item 7.01 item 8.01 item 9.01 ◈ Material Agreements ×2

VYNE announces $88M PIPE funding and positive clinical data for VYN201 and VYN202

Raised $88M gross from PIPE led by Access Biotechnology, with participation from healthcare investors.
May 11, 2023, 7:59 PM ET earnings materiality 0.60 neutral item 2.02 item 9.01 ◈ Earnings Releases

VYNE Therapeutics reports Q1 2023 net loss of $5.6M; VYN201 Phase 1b data expected Q3 2023

Q1 2023 GAAP net loss $5.6M vs net income $4.7M in Q1 2022; loss from continuing ops improved to $5.6M from $8.7M.
May 1, 2023, 7:59 PM ET other material materiality 0.60 positive item 1.01 item 7.01 item 9.01 ◈ Material Agreements

VYNE Therapeutics licenses BD2-selective BET inhibitors, selects development candidate VYN202

$3.75M upfront payment for exclusive worldwide license; up to $68.75M in milestones plus tiered royalties.
March 9, 2023, 6:59 PM ET earnings materiality 0.60 neutral item 2.02 item 9.01 ◈ Earnings Releases

VYNE reports FY2022 net loss $23.2M; VYN201 Phase 1b in vitiligo dosing

GAAP net loss of $23.2M for FY2022 vs $73.3M in 2021; adjusted net loss $18.9M.
February 10, 2023, 6:59 PM ET other material materiality 0.65 negative item 3.03 item 5.03 item 9.01 ◈ Governance Changes

VYNE Therapeutics completes 1:18 reverse stock split, reducing shares to ~3.25M

1:18 reverse stock split effective Feb 10, 2023; shares outstanding drop from 58.5M to ~3.25M.
November 10, 2022, 6:59 PM ET earnings materiality 0.70 neutral item 2.02 item 7.01 item 9.01 ◈ Earnings Releases

VYNE Q3 net loss $9.5M; VYN201 Phase 1a/b enrollment imminent; FMX114 strategy under review

Q3 2022 net loss $9.5M vs $21.3M; operating loss $9.3M vs $14.3M year-over-year.
August 30, 2022, 7:59 PM ET regulatory materiality 0.75 negative item 3.01 item 8.01

VYNE receives Nasdaq extension to Feb 2023; pays Tay £850k for BETi compounds

Nasdaq granted 180-day extension until Feb 27, 2023 to regain minimum $1.00 bid price for 10 consecutive days.
August 10, 2022, 7:59 PM ET other material materiality 0.75 negative item 5.07 item 8.01 item 9.01

VYNE's FMX114 Phase 2a AD trial misses primary endpoint; shareholders reject reverse stock split

Phase 2a trial of FMX114 for mild-to-moderate atopic dermatitis did not meet primary endpoint (ADSI change at week 4, p=0.228).
June 17, 2022, 7:59 PM ET other material materiality 0.65 neutral item 1.01 item 8.01 item 9.01

VYNE completes Phase 2a enrollment for FMX114; extends In4Derm Oral BETi option to Feb 2023

Enrollment completed in Phase 2a trial of FMX114 for mild-to-moderate atopic dermatitis; top-line results expected in 6-8 weeks.
May 12, 2022, 7:59 PM ET earnings materiality 0.70 neutral item 2.02 item 9.01

VYNE Q1 continuing ops loss $8.7M; divested MST franchise for $25M; positive FMX114 Phase 1b data

Q1 2022 GAAP loss from continuing ops $8.7M ($7.4M adjusted); net income $4.7M reflecting divestiture gain.
April 7, 2022, 7:59 PM ET other material materiality 0.65 neutral item 4.01 item 8.01 item 9.01

VYNE reports positive Phase 1b data for FMX114 in atopic dermatitis; appoints Baker Tilly as auditor after PwC dismissal

FMX114 showed statistically significant reduction in ADSI score at week 2: -81.4% mean reduction vs -54.3% for vehicle (p=0.004).
March 30, 2022, 7:59 PM ET other material materiality 0.75 positive item 8.01 item 9.01

VYNE reports positive preclinical RA data for pan-BET inhibitor VYN201; on track for H2 2022 Ph1

VYN201 intra-articular injection showed statistically significant inhibition of paw thickening at 1 and 10 mg/kg (p<0.01).
March 17, 2022, 7:59 PM ET earnings materiality 0.70 neutral item 2.02 item 9.01

VYNE Therapeutics reports FY2021 revenue $14.8M, net loss $73.3M; pipeline progress

FY2021 revenue $14.8M (down 30% YoY); net loss $73.3M, adjusted net loss $65.2M; EPS -$1.42.
March 15, 2022, 7:59 PM ET other material materiality 0.70 neutral item 1.01 item 5.02 item 9.01 ◈ executive_change

VYNE Therapeutics enters $30M equity line with Lincoln Park Capital; names Tyler Zeronda CFO

Up to $30M of common stock can be sold to Lincoln Park over 36 months; 1,667,593 commitment shares issued.

Executive changes

Appointed

Rebecca Frey

Chief Executive Officer

VYNE · VYNE Therapeutics Inc.

Effective: 2026-07-27
Filed: July 28, 2026, 5:11 PM ET

the Board appointed Rebecca Frey, Pharm.D. as the Company’s Chief Executive Officer

Appointed

Steven Ryder

Chief Medical Officer

VYNE · VYNE Therapeutics Inc.

Effective: 2026-07-27
Filed: July 28, 2026, 5:11 PM ET

the Board appointed Rebecca Frey, Pharm.D. as the Company’s Chief Executive Officer, Tyler Zeronda as the Company's Chief Financial Officer, Steven Ryder, M.D. as the Company's Chief Medical Officer

Departed

David Domzalski

President and Chief Executive Officer

VYNE · VYNE Therapeutics Inc.

Effective: 2026-07-27
Successor: Rebecca Frey
Filed: July 28, 2026, 5:11 PM ET

each of David Domzalski, VYNE’s President and Chief Executive Officer, Iain Stuart, Ph.D., VYNE’s Chief Scientific Officer, and Mutya Harsch, VYNE’s Chief Legal Officer and General Counsel, resigned as executive officers at the Closing and their employment was terminated effective July 27, 2026

Departed

Mutya Harsch

Chief Legal Officer and General Counsel

VYNE · VYNE Therapeutics Inc.

Effective: 2026-07-27
Filed: July 28, 2026, 5:11 PM ET

each of David Domzalski, VYNE’s President and Chief Executive Officer, Iain Stuart, Ph.D., VYNE’s Chief Scientific Officer, and Mutya Harsch, VYNE’s Chief Legal Officer and General Counsel, resigned as executive officers at the Closing and their employment was terminated effective July 27, 2026

Departed

Iain Stuart

Chief Scientific Officer

VYNE · VYNE Therapeutics Inc.

Effective: 2026-07-27
Filed: July 28, 2026, 5:11 PM ET

each of David Domzalski, VYNE’s President and Chief Executive Officer, Iain Stuart, Ph.D., VYNE’s Chief Scientific Officer, and Mutya Harsch, VYNE’s Chief Legal Officer and General Counsel, resigned as executive officers at the Closing and their employment was terminated effective July 27, 2026

Appointed

Tyler Zeronda

Chief Financial Officer

VYNE · VYNE Therapeutics Inc.

Effective: 2026-07-27
Filed: July 28, 2026, 5:11 PM ET

the Board appointed Rebecca Frey, Pharm.D. as the Company’s Chief Executive Officer, Tyler Zeronda as the Company's Chief Financial Officer

Appointed

Rachael Alford

Chief Operating Officer

VYNE · VYNE Therapeutics Inc.

Effective: 2026-07-27
Filed: July 28, 2026, 5:11 PM ET

the Board appointed Rebecca Frey, Pharm.D. as the Company’s Chief Executive Officer, Tyler Zeronda as the Company's Chief Financial Officer, Steven Ryder, M.D. as the Company's Chief Medical Officer, Lori Payton, Ph.D. as the Company's Chief Development Officer and Rachael Alford, Ph.D. as the Company's Chief Operating Officer

Appointed

Lori Payton

Chief Development Officer

VYNE · VYNE Therapeutics Inc.

Effective: 2026-07-27
Filed: July 28, 2026, 5:11 PM ET

the Board appointed Rebecca Frey, Pharm.D. as the Company’s Chief Executive Officer, Tyler Zeronda as the Company's Chief Financial Officer, Steven Ryder, M.D. as the Company's Chief Medical Officer, Lori Payton, Ph.D. as the Company's Chief Development Officer

Appointed

Christine Borowski

Director

VYNE · VYNE Therapeutics Inc.

Effective: 2024-01-01
Filed: January 3, 2024, 6:59 PM ET

On December 29, 2023, the Board appointed Dr. Christine Borowski to serve as a Class II director of the Company, effective as of January 1, 2024

Appointed

Tyler Zeronda

Chief Financial Officer and Treasurer

VYNE · VYNE Therapeutics Inc.

Effective: 2022-03-14
Filed: March 15, 2022, 7:59 PM ET

On March 14, 2022, the Company named Tyler Zeronda as the Chief Financial Officer and Treasurer of the Company effective immediately.

Departed

Rex Bright

Director

VYNE · VYNE Therapeutics Inc.

Effective: 2022-01-11
Filed: January 14, 2022, 6:59 PM ET

The Company deeply regrets to announce that Mr. Rex Bright passed away on January 11, 2022.

Earnings & guidance

2025-Q2 EPS reported -$0.34 filing →

Materiality & sentiment trend

Max materiality 1.00 · Median 0.65 · Most common event other_material

7 positive 10 negative 33 neutral

source · VYNE on sec.gov